Drug Profile
Research programme: metabolic and lipid disorder therapeutics - Dominari Holdings
Alternative Names: SPX 100; SPX 10624258; SPX 723; SPX 7233801; SPX 8522876; SPX 8818309; SPX 8818440; SPX-106; SPX-106TLatest Information Update: 31 Mar 2023
Price :
$50
*
At a glance
- Originator University of Kentucky Research Foundation
- Developer Dominari Holdings
- Class Hexoses; Small molecules
- Mechanism of Action Iron chelating agents; Lipid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Abdominal aortic aneurysm; Atherosclerosis; Diabetes mellitus; Dyslipidaemias; Metabolic syndrome; Obesity
Most Recent Events
- 05 Mar 2020 Spherix is now called AIkido Pharma
- 16 Jul 2016 No recent reports of development identified for preclinical development in Abdominal-aortic-aneurysm in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Atherosclerosis in USA